Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
- CHAPTER 2 MARKET OVERVIEW AND DYNAMICS
- The Top 20 cancer therapy brands - 2006
- The current market situation
- The Top 20 cancer therapy brands - 2016
- Sales by class
- Molecular targeted therapies set to dominate over the forecast period
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- 5EU
- Seven major markets
- Sales by country
- Other countries slowly catching up with the lucrative US market
- Brands by class and mode of action
- Cytotoxic therapies still make up the majority of the forecasted
cancer therapy brands
- Brands by indication
- Breast cancer drugs strongly dominate among the forecasted cancer
therapy brands
- Brands by company
- AstraZeneca and Roche are behind the highest number of forecasted
cancer therapy brands
- Brands by event
- Avastin set to experience the highest number of different events over
the forecast period
- Brands by compound annual growth rate
- Molecular targeted therapies are driving the positive CAGR for the
forecasted cancer therapy brands
- CHAPTER 3 MARKET DEFINITION
- Market definition for this report
- Cytotoxic therapies
- L1A - Alkylating agents
- L1B - Antimetabolites
- L1C - Vinca alkaloids and other plant-derived products
- L1D - Antineoplastic antibiotics
- L1X2 - Platinum compounds
- Antihormonal therapies
- L2A3 - Luteinizing hormone-releasing hormone analogs
- L2B1 - Anti-estrogens
- L2B2 - Anti-androgens
- L2B3 - Aromatase inhibitors
- Molecular targeted therapies
- L1X3 - Antineoplastic monoclonal antibodies
- L1X9 - All other antineoplastics
- CHAPTER 4 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the cancer market
- Global opportunities and threats
- US: opportunities and threats
- Japan: opportunities and threats
- 5EU: opportunities and threats
- France: opportunities and threats
- Germany: opportunities and threats
- Italy: opportunities and threats
- Spain: opportunities and threats
- UK: opportunities and threats
- Summary of environmental issues affecting the cancer market size
- CHAPTER 5 FORECAST ANALYSIS
- Country-specific assumptions and events
- Effect of Medicare Modernization Act in the US
- Biennial price cuts in Japan
- Generic erosion assumptions
- Product-specific assumptions and events
- Cytotoxic therapies
- Abraxane (ABX-007; Abraxis BioScience/AstraZeneca)
- Alimta (Pemetrexed; Eli Lilly)
- Camptosar/Campto (Irinotecan; Pfizer/Yakult/Daiichi)
- Doxil/Caelyx (Pegylated liposomal doxorubicin; Johnson &
Johnson/Schering-Plough)
- Ellence/Farmorubicin (Epirubicin; Pfizer)
- Eloxatin (Oxaliplatin; Sanofi-Aventis)
- Furtulon (Doxifluridine; Roche/Chugai)
- Gemzar (Gemcitabine; Eli Lilly)
- Navelbine (Vinorelbine; Pierre Fabre/GlaxoSmithKline)
- Paraplatin (Carboplatin; Bristol-Myers Squibb)
- Taxol (Paclitaxel; Bristol-Myers Squibb)
- Taxotere (Docetaxel; Sanofi-Aventis)
- Temodar/Temodal (Temozolomide; Schering-Plough)
- TS-1 (Tegafur, gimeracil & oteracil; Taiho
Pharmaceuticals/Sanofi-Aventis)
- UFT (Tegafur & uracil; Taiho Pharmaceuticals)
- Xeloda (Capecitabine; Roche)
- Antihormonal therapies
- Arimidex (Anastrozole; AstraZeneca)
- Aromasin (Exemestane; Pfizer)
- Casodex (Bicalutamide; AstraZeneca)
- Femara (Letrozole; Novartis)
- Lupron (Leuprorelin; Takeda/TAP/Abbott/Wyeth)
- Nolvadex (Tamoxifen; AstraZeneca)
- Zoladex (Goserelin; AstraZeneca)
- Molecular targeted therapies
- Avastin (Bevacizumab; Genentech/Roche)
- Erbitux (Cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono)
- Gleevec/Glivec (Imatinib; Novartis)
- Herceptin (Trastuzumab; Genentech/Roche)
- Iressa (Gefitinib; AstraZeneca)
- Nexavar (Sorafenib; Onyx Pharmaceuticals/Bayer Schering)
- Rituxan/MabThera (Rituximab; Biogen Idec/Genentech/Roche)
- Sutent (Sunitinib; Pfizer)
- Tarceva (Erlotinib; OSI Pharmaceuticals/Genentech/Roche)
- Tykerb (Lapatinib; GlaxoSmithKline)
- Vectibix (Panitumumab; Amgen)
- Velcade (Bortezomib; Ortho Biotech/Millennium Pharmaceuticals)
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Derivation of sales forecasts and pricing trends
- Forecasts
- Forecast methodology
- BIBLIOGRAPHY
- APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Cytotoxic therapies market data
- Antihormonal therapies market data
- Molecular targeted therapies market data
- APPENDIX B - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- 5EU forecasts
- Seven major market forecasts
- APPENDIX C
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- Disclaimer
- List of Tables
- Table 1: Top 20 cancer therapy brands in the US, Japan, Germany and
France, 2006
- Table 2: Top 20 cancer therapy brands in Italy, Spain, the UK,
collective 5EU and collective seven major markets, 2006
- Table 3: Newly marketed drugs included in the Top 20 cancer therapy
brands, 2006-2017
- Table 4: Seven major market sales of Top 20 cancer therapy brands by
drug class, 2006
- Table 5: Molecular targeted therapies included in the Top 20 cancer
therapy brands, 2006
- Table 6: Cytotoxic therapies included in the Top 20 cancer therapy
brands, 2006
- Table 7: Antihormonal therapies included in the Top 20 cancer therapy
brands, 2006
- Table 8: Top 20 cancer therapy brands in the US, Japan, Germany and
France, 2016
- Table 9: Top 20 cancer therapy brands in Italy, Spain, the UK,
collective 5EU and collective seven major markets, 2006
- Table 10: Forecasted cancer therapy brands by number of different
events, 2007-2016
- Table 11: Definition of the cancer market, 2007
- Table 12: Abraxane: key facts
- Table 13: Alimta: key facts
- Table 14: Camptosar: key facts
- Table 15: Doxil: key facts
- Table 16: Ellence: key facts
- Table 17: Eloxatin: key facts
- Table 18: Furtulon: key facts
- Table 19: Gemzar: key facts
- Table 20: Navelbine: key facts
- Table 21: Paraplatin: key facts
- Table 22: Taxol: key facts
- Table 23: Taxotere: key facts
- Table 24: Market share of Taxotere, 2005
- Table 25: Temodar: key facts
- Table 26: TS-1: key facts
- Table 27: UFT: key facts
- Table 28: Xeloda: key facts
- Table 29: Arimidex: key facts
- Table 30: Aromasin: key facts
- Table 31: Casodex: key facts
- Table 32: Femara: key facts
- Table 33: Lupron: key facts
- Table 34: Nolvadex: key facts
- Table 35: Zoladex: key facts
- Table 36: Avastin: key facts
- Table 37: Erbitux: key facts
- Table 38: Gleevec: key facts
- Table 39: Herceptin: key facts
- Table 40: Iressa: key facts
- Table 41: Nexavar: key facts
- Table 42: Rituxan: key facts
- Table 43: Approved indications for Rituxan in the US and EU, 2006
- Table 44: Sutent: key facts
- Table 45: Tarceva: key facts
- Table 46: Tykerb: key facts
- Table 47: Vectibix: key facts
- Table 48: Velcade: key facts
- Table 49: Abraxane: key facts
- Table 50: Alimta: key facts
- Table 51: Camptosar: key facts
- Table 52: Doxil: key facts
- Table 53: Ellence: key facts
- Table 54: Eloxatin: key facts
- Table 55: Furtulon: key facts
- Table 56: Gemzar: key facts
- Table 57: Navelbine: key facts
- Table 58: Paraplatin: key facts
- Table 59: Taxol: key facts
- Table 60: Taxotere: key facts
- Table 61: Temodar: key facts
- Table 62: TS-1: key facts
- Table 63: UFT: key facts
- Table 64: Xeloda: key facts
- Table 65: Arimidex: key facts
- Table 66: Aromasin: key facts
- Table 67: Casodex: key facts
- Table 68: Femara: key facts
- Table 69: Lupron: key facts
- Table 70: Nolvadex: key facts
- Table 71: Zoladex: key facts
- Table 72: Avastin: key facts
- Table 73: Erbitux: key facts
- Table 74: Gleevec: key facts
- Table 75: Herceptin: key facts
- Table 76: Iressa: key facts
- Table 77: Nexavar: key facts
- Table 78: Rituxan: key facts
- Table 79: Sutent: key facts
- Table 80: Tarceva: key facts
- Table 81: Tykerb: key facts
- Table 82: Vectibix: key facts
- Table 83: Velcade: key facts
- Table 84: US forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 85: US forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 86: Japan forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 87: Japan forecasts for the Top 20 cancer therapy brands($m),
2006-2016 (2 of 2)
- Table 88: France forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 89: France forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 90: Germany forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 91: Germany forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 92: Italy forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 93: Italy forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 94: Spain forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 95: Spain forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 96: UK forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 97: UK forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (2 of 2)
- Table 98: 5EU forecasts for the Top 20 cancer therapy brands ($m),
2006-2016 (1 of 2)
- Table 99: 5EU forecasts for the Top 20 cancer therapy brands ($m),
2006-2016
- Table 100: Seven major market forecasts for the Top 20 cancer therapy
brands ($m), 2006-2016 (1 of 2)
- Table 101: Seven major market forecasts for the Top 20 cancer therapy
brands ($m), 2006-2016 (2 of 2)
- List of Figures
- Figure 1: US Top 20 cancer therapy brand sales by class: 2006
- Figure 2: US Top 20 cancer therapy brand sales by class: 2016
- Figure 3: Japan Top 20 cancer therapy brand sales by class: 2006
- Figure 4: Japan Top 20 cancer therapy brand sales by class: 2016
- Figure 5: France Top 20 cancer therapy brand sales by class: 2006
- Figure 6: France Top 20 cancer therapy brand sales by class: 2016
- Figure 7: Germany Top 20 cancer therapy brand sales by class: 2006
- Figure 8: Germany Top 20 cancer therapy brand sales by class: 2016
- Figure 9: Italy Top 20 cancer therapy brand sales by class: 2006
- Figure 10: Italy Top 20 cancer therapy brand sales by class: 2016
- Figure 11: Spain Top 20 cancer therapy brand sales by class: 2006
- Figure 12: Spain Top 20 cancer therapy brand sales by class: 2016
- Figure 13: UK Top 20 cancer therapy brand sales by class: 2006
- Figure 14: UK Top 20 cancer therapy brand sales by class: 2016
- Figure 15: 5EU Top 20 cancer therapy brand sales by class: 2006
- Figure 16: 5EU Top 20 cancer therapy brand sales by class: 2016
- Figure 17: Seven major markets Top 20 cancer therapy brand sales by
class: 2006
- Figure 18: Seven major markets Top 20 cancer therapy brand sales by
class: 2016
- Figure 19: Top 20 cancer therapy brand sales by country: 2006
- Figure 20: Top 20 cancer therapy brand sales by country: 2016
- Figure 21: Forecasted cancer therapy brands by class
- Figure 22: Forecasted cancer therapy brands by mode of action
- Figure 23: Forecasted cancer therapy brands by indication
- Figure 24: Forecasted cancer therapy brands by company
- Figure 25: Forecasted cancer therapy brands by number of different
events, 2007-2016
- Figure 26: Forecasted cancer therapy brands by CAGR, 2006-2016
- Figure 27: Molecular targeted therapy brands by CAGR, 2006-2016
- Figure 28: Cytotoxic therapy brands by CAGR, 2006-2016
- Figure 29: Antihormonal therapy brands by CAGR, 2006-2016
- Figure 30: Seven market population aged 60 and over, 2000-2050
- Figure 31: Forecast incidence of cancer across the seven major
pharmaceutical markets, 2001-2015
- Figure 32: Global oncology sales ($m), 2002-2011
- Figure 33: Summary of global opportunities and threats affecting the
cancer market, 2007
- Figure 34: Summary of regional opportunities and threats affecting the
cancer market, 2007
|
Related Report
|
View Cart
